• PDF: Delivered by email usually within 12 to 24 UK business hours.

Sorin S.p.A. Product Pipeline Analysis

Sorin S.p.A. Product Pipeline Analysis

Sorin S.p.A. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Scope's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.
  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.
  • Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.
  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
  • 3 Sorin S.p.A. Pipeline Products
    • 3.1 Sorin S.p.A. Product Pipeline Analysis
      • 3.1.1 Sorin S.p.A. Pipeline Products By Equipment Type
      • 3.1.2 Sorin S.p.A. Pipeline Products By Development Stage
      • 3.1.3 Sorin S.p.A. Pipeline Products By Therapy Area
      • 3.1.4 Sorin S.p.A. Pipeline Products By Clinical Trials
      • 3.1.5 Sorin S.p.A. Pipeline Products By News Summary
    • 3.2 REPLY Pacemakers
      • 3.2.1 Product Status
      • 3.2.2 Product Description
      • 3.2.3 Product Milestone
      • 3.2.4 Clinical Trials
    • 3.3 Paradym CRT-D
      • 3.3.1 Product Status
      • 3.3.2 Product Description
      • 3.3.3 Product Milestone
      • 3.3.4 Product Patent Details
    • 3.4 Janus SRT
      • 3.4.1 Product Status
      • 3.4.2 Product Description
    • 3.5 Stentless Biological Heart Valve Prosthesis
      • 3.5.1 Product Status
      • 3.5.2 Product Description
      • 3.5.3 Product Milestone
      • 3.5.4 Clinical Trials
    • 3.6 Perceval S
      • 3.6.1 Product Status
      • 3.6.2 Product Description
      • 3.6.3 Clinical Trials
      • 3.6.4 Product Patent Details
    • 3.7 SYNDELI VR
      • 3.7.1 Product Status
      • 3.7.2 Product Description
    • 3.8 SYNDELI DR
      • 3.8.1 Product Status
      • 3.8.2 Product Description
    • 3.9 SYNDELI CRT-D
      • 3.9.1 Product Status
      • 3.9.2 Product Description
    • 3.10 2nd generation DES
      • 3.10.1 Product Status
      • 3.10.2 Product Description
      • 3.10.3 Product Patent Details
    • 3.11 Janus 2nd generation
      • 3.11.1 Product Status
      • 3.11.2 Product Description
      • 3.11.3 Product Milestone
      • 3.11.4 Clinical Trials
      • 3.11.5 Product Patent Details
    • 3.12 Hi Performance ICD
      • 3.12.1 Product Status
      • 3.12.2 Product Description
    • 3.13 Hi Performance CRT-D
      • 3.13.1 Product Status
      • 3.13.2 Product Description
    • 3.14 Percutaneous valve
      • 3.14.1 Product Status
      • 3.14.2 Product Description
    • 3.15 Paradym resynchronizer
      • 3.15.1 Product Status
      • 3.15.2 Product Description
      • 3.15.3 Product Patent Details
    • 3.16 S80TB
      • 3.16.1 Product Status
      • 3.16.2 Product Description
      • 3.16.3 Clinical Trials
    • 3.17 Next generation CRT-D
      • 3.17.1 Product Status
      • 3.17.2 Product Description
      • 3.17.3 Product Patent Details
    • 3.18 Isoline ICD Lead
      • 3.18.1 Product Status
      • 3.18.2 Product Description
    • 3.19 Paradym CRT-D sonR
      • 3.19.1 Product Status
      • 3.19.2 Product Description
      • 3.19.3 Product Patent Details
    • 3.20 LV Bipolar Lead
      • 3.20.1 Product Status
      • 3.20.2 Product Description
    • 3.21 Paradym CRT PhD
      • 3.21.1 Product Status
      • 3.21.2 Product Description
    • 3.22 New ICD Lead
      • 3.22.1 Product Status
      • 3.22.2 Product Description
    • 3.23 Spiderflash AFIB
      • 3.23.1 Product Status
      • 3.23.2 Product Description
    • 3.24 XFine
      • 3.24.1 Product Status
      • 3.24.2 Product Description
      • 3.24.3 Clinical Trials
    • 3.25 Beflex
      • 3.25.1 Product Status
      • 3.25.2 Product Description
      • 3.25.3 Clinical Trials
    • 3.26 SonRFix
      • 3.26.1 Product Status
      • 3.26.2 Product Description
      • 3.26.3 Clinical Trials
    • 3.27 HLM S5 accessories
      • 3.27.1 Product Status
      • 3.27.2 Product Description
  • 4 Recent Developments
    • 4.1 Product News
      • 4.1.1 Nov 26, 2008: Sorin Group Announces European Market Release And First Implant Of New-Generation Cardiac Resynchronization Therapy Defibrillator
      • 4.1.2 Sep 22, 2008: Sorin Group Announces First Patient Enrolment In The E-Optima Registry
      • 4.1.3 Sep 16, 2008: Sorin Group Announces The Publication Of Superior 21 Year Durability Data With The Mitroflow Valve In Peer-Reviewed Medical Journal
      • 4.1.4 Sep 12, 2008: Sorin Group Announces First Successful Use Of New Pediatric Oxygenator At Children's Medical Center Dallas
      • 4.1.5 Sep 12, 2008: Sorin Group Announces Successful Use Of New Pediatric Arterial Filter At Children's Medical Center Dallas
      • 4.1.6 Aug 07, 2008: Sorin Group Announces FDA Approval And First US Implant Of The Dual Chamber Pacemaker
      • 4.1.7 May 21, 2008: Sorin Group Reports FDA Approval Of Ovatio CRT
      • 4.1.8 May 16, 2008: Sorin Group Announces FDA Approval Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator OVATIO CRT
      • 4.1.9 Apr 28, 2008: Sorin Group Cardiac Rhythm Management Announces First Implant Of A New-Generation CRT-D Device Designed To Provide Hemodynamic Management Of Heart Failure
      • 4.1.10 Mar 07, 2008: Sorin Group Announces FDA Approval Of New Defibrillation Leads Range: ISOLINE
      • 4.1.11 Feb 14, 2008: Sorin Group Announces US Clinical Trial Of Memo 3D Semirigid Annuloplasty Ring
      • 4.1.12 Dec 31, 2007: Mitroflow Aortic Pericardial Heart Valve Gets US FDA Approval In United states
      • 4.1.13 Dec 05, 2007: Sorin Group Announces First US Implant Of Mitroflow Aortic Pericardial Heart Valve
      • 4.1.14 Dec 03, 2007: Sorin Group Cardiac Rhythm Management Announces The First US Enrollment In The Option Study
      • 4.1.15 Oct 22, 2007: Sorin Group Announces The First US Clinical Implant Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator OVATIO CRT
      • 4.1.16 Oct 22, 2007: Sorin Group Announces The First US Clinical Implant Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator Ovatio CRT
      • 4.1.17 Sep 25, 2007: Sorin Group Announces US FDA's Authorization To Market Its Memo 3D Annuloplasty Ring In the United States
      • 4.1.18 Aug 31, 2007: Sorin Group Launches World's Smallest Implantable Cardioverter Defibrillators In Japan
      • 4.1.19 May 09, 2007: The Sorin Group Announces European Market Release Of REPLY, The World's Smallest Pacemaker
      • 4.1.20 Mar 08, 2007: First Implants And EU Approval For Sorin REPLY Pacemakers
      • 4.1.21 Dec 07, 2006: Sorin Group: ELA Medical, Inc. Files PMA Submission For OVATIO CRT
      • 4.1.22 Jun 05, 2006: Sorin Group Announces The Start Of Enrolment In The e-JAMI Registry And Presents The MASTER Trial; e-JAMI Registry Will Involve 500 AMI Patients Treated With Janus Flex Stent in Real Clinical Practice
      • 4.1.23 Oct 04, 2005: Sorin Group Innovates In The Hemodynamic Management Of Heart Failure With The European Introduction Of Its New Generation Cardiac Resynchronization Therapy Products
      • 4.1.24 Jun 20, 2005: Sorin Group Presents At The Third Edition Of The Biannual Meeting Of The Society For Heart Valve Disease, In Vancouver
      • 4.1.25 May 19, 2005: Sorin Group: ELA Medical Announces The First Worldwide Implant Of A New ICD For Heart Failure Patients (CRT-D)
    • 4.2 Product Approvals
      • 4.2.1 Aug 07, 2008: Sorin Group Announces FDA Approval And First US Implant Of The Dual Chamber Pacemaker
      • 4.2.2 May 21, 2008: Sorin Group Reports FDA Approval Of Ovatio CRT
      • 4.2.3 May 16, 2008: Sorin Group Announces FDA Approval Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator OVATIO CRT
      • 4.2.4 Mar 07, 2008: Sorin Group Announces FDA Approval Of New Defibrillation Leads Range: ISOLINE
      • 4.2.5 Dec 31, 2007: Mitroflow Aortic Pericardial Heart Valve Gets US FDA Approval In United states
      • 4.2.6 Sep 25, 2007: Sorin Group Announces US FDA's Authorization To Market Its Memo 3D Annuloplasty Ring In the United States
      • 4.2.7 Mar 08, 2007: First Implants And EU Approval For Sorin REPLY Pacemakers
    • 4.3 Clinical Trials
      • 4.3.1 Sep 22, 2008: Sorin Group Announces First Patient Enrolment In The E-Optima Registry
      • 4.3.2 Apr 28, 2008: Sorin Group Cardiac Rhythm Management Announces First Implant Of A New-Generation CRT-D Device Designed To Provide Hemodynamic Management Of Heart Failure
      • 4.3.3 Feb 14, 2008: Sorin Group Announces US Clinical Trial Of Memo 3D Semirigid Annuloplasty Ring
      • 4.3.4 Dec 03, 2007: Sorin Group Cardiac Rhythm Management Announces The First US Enrollment In The Option Study
      • 4.3.5 Oct 22, 2007: Sorin Group Announces The First US Clinical Implant Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator Ovatio CRT
      • 4.3.6 Oct 22, 2007: Sorin Group Announces The First US Clinical Implant Of The World's Smallest Cardiac Resynchronization Implantable Cardioverter Defibrillator OVATIO CRT
      • 4.3.7 Jun 05, 2006: Sorin Group Announces The Start Of Enrolment In The e-JAMI Registry And Presents The MASTER Trial; e-JAMI Registry Will Involve 500 AMI Patients Treated With Janus Flex Stent in Real Clinical Practice
      • 4.3.8 May 19, 2005: Sorin Group: ELA Medical Announces The First Worldwide Implant Of A New ICD For Heart Failure Patients (CRT-D)
  • 5 Appendix
    • 5.1 Methodology
      • 5.1.1 Coverage
      • 5.1.2 Secondary Research
      • 5.1.3 Primary Research
      • 5.1.4 Expert Panel Validation
    • 5.2 Contact Us
    • 5.3 About Global Markets Direct
    • 5.4 Disclaimer
  • 1 List of Tables
    • Table 1: Sorin S.p.A.,Key Facts, 2007
    • Table 2: Sorin S.p.A. Pipeline Products by Equipment Type
    • Table 3: Sorin S.p.A. Pipeline Products By Development Stage
    • Table 4: Sorin S.p.A. Pipeline Products By Therapy Area
    • Table 5: Sorin S.p.A. Pipeline Products By Clinical Trials
    • Table 6: Sorin S.p.A. Pipeline Products By News Summaries
    • Table 7: REPLY Pacemakers, Product Status
    • Table 8: REPLY Pacemakers, Product Description
    • Table 9: REPLY PacemakersClinical Trials 1
    • Table 10: Paradym CRT-D, Product Status
    • Table 11: Paradym CRT-D, Product Description
    • Table 12: Paradym CRT-D Patent Details
    • Table 13: Janus SRT, Product Status
    • Table 14: Janus SRT, Product Description
    • Table 15: Stentless Biological Heart Valve Prosthesis, Product Status
    • Table 16: Stentless Biological Heart Valve Prosthesis, Product Description
    • Table 17: Stentless Biological Heart Valve ProsthesisClinical Trials 1
    • Table 18: Perceval S, Product Status
    • Table 19: Perceval S, Product Description
    • Table 20: Perceval SClinical Trials 1
    • Table 21: Perceval S Patent Details
    • Table 22: SYNDELI VR, Product Status
    • Table 23: SYNDELI VR, Product Description
    • Table 24: SYNDELI DR, Product Status
    • Table 25: SYNDELI DR, Product Description
    • Table 26: SYNDELI CRT-D, Product Status
    • Table 27: SYNDELI CRT-D, Product Description
    • Table 28: 2nd generation DES, Product Status
    • Table 29: 2nd generation DES, Product Description
    • Table 30: 2nd generation DES Patent Details
    • Table 31: Janus 2nd generation, Product Status
    • Table 32: Janus 2nd generation, Product Description
    • Table 33: Janus 2nd generationClinical Trials 1
    • Table 34: Janus 2nd generation Patent Details
    • Table 35: Hi Performance ICD, Product Status
    • Table 36: Hi Performance ICD, Product Description
    • Table 37: Hi Performance CRT-D, Product Status
    • Table 38: Hi Performance CRT-D, Product Description
    • Table 39: Percutaneous valve, Product Status
    • Table 40: Percutaneous valve, Product Description
    • Table 41: Paradym resynchronizer, Product Status
    • Table 42: Paradym resynchronizer, Product Description
    • Table 43: Paradym resynchronizer Patent Details
    • Table 44: S80TB, Product Status
    • Table 45: S80TB, Product Description
    • Table 46: S80TBClinical Trials 1
    • Table 47: Next generation CRT-D, Product Status
    • Table 48: Next generation CRT-D, Product Description
    • Table 49: Next generation CRT-D Patent Details
    • Table 50: Isoline ICD Lead, Product Status
    • Table 51: Isoline ICD Lead, Product Description
    • Table 52: Paradym CRT-D sonR, Product Status
    • Table 53: Paradym CRT-D sonR, Product Description
    • Table 54: Paradym CRT-D sonR Patent Details
    • Table 55: LV Bipolar Lead, Product Status
    • Table 56: LV Bipolar Lead, Product Description
    • Table 57: Paradym CRT PhD, Product Status
    • Table 58: Paradym CRT PhD, Product Description
    • Table 59: New ICD Lead, Product Status
    • Table 60: New ICD Lead, Product Description
    • Table 61: Spiderflash AFIB, Product Status
    • Table 62: Spiderflash AFIB, Product Description
    • Table 63: XFine, Product Status
    • Table 64: XFine, Product Description
    • Table 65: XFineClinical Trials 1
    • Table 66: Beflex, Product Status
    • Table 67: Beflex, Product Description
    • Table 68: BeflexClinical Trials 1
    • Table 69: SonRFix, Product Status
    • Table 70: SonRFix, Product Description
    • Table 71: SonRFixClinical Trials 1
    • Table 72: HLM S5 accessories, Product Status
    • Table 73: HLM S5 accessories, Product Description
    • 1.2 List of Figures
    • Figure 1: Sorin S.p.A. Pipeline Products By Equipment Type
    • Figure 2: Sorin S.p.A. Pipeline Products By Equipment Type
    • Figure 3: Sorin S.p.A. Pipeline Products By Development Stage
    • Figure 4: Sorin S.p.A. Pipeline Products By News Summary
    • Figure 5: Global Markets Direct Methodology
+44 20 8816 8548

Ask a question about Sorin S.p.A. Product Pipeline Analysis

Enter the characters you see in the picture below
Captcha